Què estàs buscant? Escriu el nom, el títol o qualsevol paraula clau que estigui relacionada amb el que estàs buscant i selecciona a quina categoria de contingut pertany. Cerca Fulltext search Activitats Professionals Grups de recerca Notícies - Qualsevol - Year 2019 Referencia Ann Transl Med. 2019 Dec;7(Suppl 8):S340. doi: 10.21037/atm.2019.09.104. Tipus publicació Editorial en revista internacional DOI http://dx.doi.org/10.21037/atm.2019.09.104 Revista Annals of Translational Medicine Títol Complet Single-cell RNA profiling of glomerular cells in diabetic kidney: a step forward for understanding diabetic nephropathy. Factor d'impacte 3.69 Grup de recerca Nefrologia i trasplantament renal Autors Maria Jose Soler Romeo Codi 12890 PMID https://pubmed.ncbi.nlm.nih.gov/32016058 Nom Autors Soler, Maria Jose, Batlle, Daniel et al. DOI número 10.21037/atm.2019.09.104 Year 2019 Referencia Front Aging Neurosci. 2020 Jan 21;11:367. doi: 10.3389/fnagi.2019.00367. eCollection 2019. Tipus publicació Revisió en revista internacional DOI http://dx.doi.org/10.3389/fnagi.2019.00367 Revista Frontiers in Aging Neuroscience Títol Complet Functional Near-Infrared Spectroscopy to Study Cerebral Hemodynamics in Older Adults During Cognitive and Motor Tasks: A Review. Factor d'impacte 3.63 Grup de recerca Recerca en envelliment, fragilitat i transicions a Barcelona Autors Marco Inzitari Luis Ignacio Soto Bargaria Laura Mónica Perez Bazan Cristina Udina Argilaga Carmina Castellano Tejedor Codi 12891 PMID https://pubmed.ncbi.nlm.nih.gov/32038224 Nom Autors Inzitari, Marco, Soto-Bagaria, Luis, Perez, Laura-Monica, Udina, Cristina, Avtzi, Stella, Durduran, Turgut, Holtzer, Roee, Rosso, Andrea L, Castellano-Tejedor, Carmina et al. DOI número 10.3389/fnagi.2019.00367 Year 2019 Referencia J Spine Surg. 2019 Dec;5(4):535-540. doi: 10.21037/jss.2019.11.12. Tipus publicació Article en revista internacional DOI http://dx.doi.org/10.21037/jss.2019.11.12 Revista Journal of spine surgery (Hong Kong) Títol Complet The effect of increasing body mass index on the pain and function of patients with adult spinal deformity. Factor d'impacte 0.00 Grup de recerca Unitat de recerca de la columna vertebral Autors Ferran Pellisé Uriquiza Codi 12892 PMID https://pubmed.ncbi.nlm.nih.gov/32043004 Nom Autors Wyatt, Michael Charles, Boissiere, Louis, Hayashi, Kazunori, Cawley, Derek Thomas, Yilgor, Caglar, Larrieu, Daniel, Fujishiro, Takashi, Alanay, Ahmet, Acaroglu, Emre, Kleinstueck, Frank et al. DOI número 10.21037/jss.2019.11.12 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.224 Revista ANNALS OF ONCOLOGY Títol Complet Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. Factor d'impacte 14.20 Codi 12893 PMID https://pubmed.ncbi.nlm.nih.gov/32085233 Nom Autors Macarulla, T, Javle, M, Borbath, I, Clarke, S, Hitre, E, Louvet, C, Valle, J, Weiss, K, Berman, C, Howland, M et al. DOI número 10.1093/annonc/mdz155.224 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.190 Revista ANNALS OF ONCOLOGY Títol Complet Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). Factor d'impacte 14.20 Codi 12894 PMID https://pubmed.ncbi.nlm.nih.gov/32085197 Nom Autors Maurel, J, Taberner, M, Rodriguez-Salas, N, Aparicio, J, Virgili, A, Capdevila, J, Munoz Boza, F, Alvarez, R, Bosch, C, Camara, J et al. DOI número 10.1093/annonc/mdz155.190 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv51-iv52. doi: 10.1093/annonc/mdz155.189. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.189 Revista ANNALS OF ONCOLOGY Títol Complet Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients. Factor d'impacte 14.20 Codi 12895 PMID https://pubmed.ncbi.nlm.nih.gov/32085195 Nom Autors de Toro Carmena, M, Ortega Moran, L, Garcia Adrian, S, Castanon Lopez, C, Molina Villaverde, R, Marrupe Gonzalez, D, Lopez Munoz, A, Alcaraz Nunes, D, Diaz Beveridge, R, Lopez Alfonso, A et al. DOI número 10.1093/annonc/mdz155.189 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv25. doi: 10.1093/annonc/mdz155.093. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.093 Revista ANNALS OF ONCOLOGY Títol Complet KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study. Factor d'impacte 14.20 Codi 12896 PMID https://pubmed.ncbi.nlm.nih.gov/32085099 Nom Autors Chung, H, Bang, Y, Fuchs, C, Qin, S, Satoh, T, Shitara, K, Tabernero, J, Van Cutsem, E, Cao, Z, Chen, X et al. DOI número 10.1093/annonc/mdz155.093 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv154. doi: 10.1093/annonc/mdz183.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183.004 Revista ANNALS OF ONCOLOGY Títol Complet BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. Factor d'impacte 14.20 Codi 12897 PMID https://pubmed.ncbi.nlm.nih.gov/32085058 Nom Autors Anderson, L, Tabernero, J, Christy-Bittel, J, Sandor, V, Garcia Alfonso, P, Arkenau, H, Kopetz, S, Grothey, A, Van Cutsem, E, Wasan, H et al. DOI número 10.1093/annonc/mdz183.004 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv152-iv153. doi: 10.1093/annonc/mdz183.001. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183.001 Revista ANNALS OF ONCOLOGY Títol Complet Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Factor d'impacte 14.20 Codi 12898 PMID https://pubmed.ncbi.nlm.nih.gov/32085055 Nom Autors Tabernero, J, Van Cutsem, E, Bang, Y, Fuchs, C, Wyrwicz, L, Lee, K, Kudaba, I, Garrido, M, Chung, H, Castro Salguero, H et al. DOI número 10.1093/annonc/mdz183.001 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv152. doi: 10.1093/annonc/mdz183. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183 Revista ANNALS OF ONCOLOGY Títol Complet Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. Factor d'impacte 14.20 Codi 12899 PMID https://pubmed.ncbi.nlm.nih.gov/32085054 Nom Autors Golan, T, Van Cutsem, E, Macarulla, T, Hall, M, Park, J, Hochhauser, D, Arnold, D, Oh, D, Reinacher-Schick, A, Tortora, G et al. DOI número 10.1093/annonc/mdz183 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv135. doi: 10.1093/annonc/mdz154.025. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.025 Revista ANNALS OF ONCOLOGY Títol Complet Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Factor d'impacte 14.20 Codi 12900 PMID https://pubmed.ncbi.nlm.nih.gov/32085044 Nom Autors Benavides, M, Cano, T, Loupakis, F, Garrote, M Rodriguez, Rivera, F, Goldberg, R, Falcone, A, Bennouna, J, Ciardiello, F, Tabernero, J et al. DOI número 10.1093/annonc/mdz154.025 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv127. doi: 10.1093/annonc/mdz154.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.004 Revista ANNALS OF ONCOLOGY Títol Complet Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Factor d'impacte 14.20 Codi 12901 PMID https://pubmed.ncbi.nlm.nih.gov/32085018 Nom Autors Harding, J, Cleary, J, Shapiro, G, Brana, I, Moreno, V, Quinn, D, Borad, M, Loi, S, Spanggaard, I, Stemmer, S et al. DOI número 10.1093/annonc/mdz154.004 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154 Revista ANNALS OF ONCOLOGY Títol Complet An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Factor d'impacte 14.20 Codi 12902 PMID https://pubmed.ncbi.nlm.nih.gov/32085016 Nom Autors Philip, P, Bruchec, Y Le, Romano, A, Goldstein, D, Reni, M, Riess, H, O'Reilly, E, Santoro, A, Bekaii-Saab, T, Tempero, M et al. DOI número 10.1093/annonc/mdz154 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154.001. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.001 Revista ANNALS OF ONCOLOGY Títol Complet Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Factor d'impacte 14.20 Codi 12903 PMID https://pubmed.ncbi.nlm.nih.gov/32085015 Nom Autors Tempero, M, Oh, D, Macarulla, T, Reni, M, Van Cutsem, E, Hendifar, A, Waldschmidt, D, Starling, N, Bachet, J, Chang, H et al. DOI número 10.1093/annonc/mdz154.001 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv125. doi: 10.1093/annonc/mdz157.009. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.009 Revista ANNALS OF ONCOLOGY Títol Complet Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. Factor d'impacte 14.20 Codi 12904 PMID https://pubmed.ncbi.nlm.nih.gov/32085014 Nom Autors Rolling, C, Garralda, E, Fiedler, W, Matos, I, Conte, G, Raspagliesi, F, Habel, B, Baumeister, H, Ochsenreither, S, Zurlo, A et al. DOI número 10.1093/annonc/mdz157.009 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv123. doi: 10.1093/annonc/mdz157.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.004 Revista ANNALS OF ONCOLOGY Títol Complet A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. Factor d'impacte 14.20 Codi 12905 PMID https://pubmed.ncbi.nlm.nih.gov/32085008 Nom Autors Wainberg, Z, Boland, P, Lieu, C, Dayyani, F, Macarulla, T, Zhang, B, Belanger, B, Moore, Y, Wang, T, Maxwell, F et al. DOI número 10.1093/annonc/mdz157.004 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv122-iv123. doi: 10.1093/annonc/mdz157.002. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.002 Revista ANNALS OF ONCOLOGY Títol Complet Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Factor d'impacte 14.20 Codi 12906 PMID https://pubmed.ncbi.nlm.nih.gov/32085006 Nom Autors Ishii, N, Hu, Y, Chessex, A Vaslin, Pokorska-Bocci, A, Nicolas, V, Kirpicheva, Y, Zanna, C, Flaherty, K, Tabernero, J, Hyman, D et al. DOI número 10.1093/annonc/mdz157.002 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv117. doi: 10.1093/annonc/mdz156.023. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz156.023 Revista ANNALS OF ONCOLOGY Títol Complet Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS. Factor d'impacte 14.20 Codi 12907 PMID https://pubmed.ncbi.nlm.nih.gov/32084991 Nom Autors Argiles, G, Tabernero, J, Sobrero, A, Ohtsu, A, Mayer, R, Vidot, L, Moreno Vera, S, Van Cutsem, E et al. DOI número 10.1093/annonc/mdz156.023 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv110. doi: 10.1093/annonc/mdz156. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz156 Revista ANNALS OF ONCOLOGY Títol Complet Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. Factor d'impacte 14.20 Codi 12908 PMID https://pubmed.ncbi.nlm.nih.gov/32084969 Nom Autors Reni, M, Winter, J, Tortora, G, Pelzer, U, Riess, H, Chang, H, O'Reilly, E, Oh, D, Diaz, I Ales, Milella, M et al. DOI número 10.1093/annonc/mdz156 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv109. doi: 10.1093/annonc/mdz155.399. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.399 Revista ANNALS OF ONCOLOGY Títol Complet ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). Factor d'impacte 14.20 Codi 12909 PMID https://pubmed.ncbi.nlm.nih.gov/32084963 Nom Autors Van Cutsem, E, Grothey, A, Yaeger, R, Paez, D, Tabernero, J, Taieb, J, Yoshino, T, Groc, M, Vedovato, J, Chetaille, E et al. DOI número 10.1093/annonc/mdz155.399 Paginació Primera pàgina « Pàgina anterior ‹ … Page 924 Page 925 Pàgina actual 926 Page 927 Page 928 … Pàgina següent › Última pàgina »
Year 2019 Referencia Ann Transl Med. 2019 Dec;7(Suppl 8):S340. doi: 10.21037/atm.2019.09.104. Tipus publicació Editorial en revista internacional DOI http://dx.doi.org/10.21037/atm.2019.09.104 Revista Annals of Translational Medicine Títol Complet Single-cell RNA profiling of glomerular cells in diabetic kidney: a step forward for understanding diabetic nephropathy. Factor d'impacte 3.69 Grup de recerca Nefrologia i trasplantament renal Autors Maria Jose Soler Romeo Codi 12890 PMID https://pubmed.ncbi.nlm.nih.gov/32016058 Nom Autors Soler, Maria Jose, Batlle, Daniel et al. DOI número 10.21037/atm.2019.09.104
Year 2019 Referencia Front Aging Neurosci. 2020 Jan 21;11:367. doi: 10.3389/fnagi.2019.00367. eCollection 2019. Tipus publicació Revisió en revista internacional DOI http://dx.doi.org/10.3389/fnagi.2019.00367 Revista Frontiers in Aging Neuroscience Títol Complet Functional Near-Infrared Spectroscopy to Study Cerebral Hemodynamics in Older Adults During Cognitive and Motor Tasks: A Review. Factor d'impacte 3.63 Grup de recerca Recerca en envelliment, fragilitat i transicions a Barcelona Autors Marco Inzitari Luis Ignacio Soto Bargaria Laura Mónica Perez Bazan Cristina Udina Argilaga Carmina Castellano Tejedor Codi 12891 PMID https://pubmed.ncbi.nlm.nih.gov/32038224 Nom Autors Inzitari, Marco, Soto-Bagaria, Luis, Perez, Laura-Monica, Udina, Cristina, Avtzi, Stella, Durduran, Turgut, Holtzer, Roee, Rosso, Andrea L, Castellano-Tejedor, Carmina et al. DOI número 10.3389/fnagi.2019.00367
Year 2019 Referencia J Spine Surg. 2019 Dec;5(4):535-540. doi: 10.21037/jss.2019.11.12. Tipus publicació Article en revista internacional DOI http://dx.doi.org/10.21037/jss.2019.11.12 Revista Journal of spine surgery (Hong Kong) Títol Complet The effect of increasing body mass index on the pain and function of patients with adult spinal deformity. Factor d'impacte 0.00 Grup de recerca Unitat de recerca de la columna vertebral Autors Ferran Pellisé Uriquiza Codi 12892 PMID https://pubmed.ncbi.nlm.nih.gov/32043004 Nom Autors Wyatt, Michael Charles, Boissiere, Louis, Hayashi, Kazunori, Cawley, Derek Thomas, Yilgor, Caglar, Larrieu, Daniel, Fujishiro, Takashi, Alanay, Ahmet, Acaroglu, Emre, Kleinstueck, Frank et al. DOI número 10.21037/jss.2019.11.12
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.224 Revista ANNALS OF ONCOLOGY Títol Complet Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. Factor d'impacte 14.20 Codi 12893 PMID https://pubmed.ncbi.nlm.nih.gov/32085233 Nom Autors Macarulla, T, Javle, M, Borbath, I, Clarke, S, Hitre, E, Louvet, C, Valle, J, Weiss, K, Berman, C, Howland, M et al. DOI número 10.1093/annonc/mdz155.224
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.190 Revista ANNALS OF ONCOLOGY Títol Complet Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). Factor d'impacte 14.20 Codi 12894 PMID https://pubmed.ncbi.nlm.nih.gov/32085197 Nom Autors Maurel, J, Taberner, M, Rodriguez-Salas, N, Aparicio, J, Virgili, A, Capdevila, J, Munoz Boza, F, Alvarez, R, Bosch, C, Camara, J et al. DOI número 10.1093/annonc/mdz155.190
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv51-iv52. doi: 10.1093/annonc/mdz155.189. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.189 Revista ANNALS OF ONCOLOGY Títol Complet Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients. Factor d'impacte 14.20 Codi 12895 PMID https://pubmed.ncbi.nlm.nih.gov/32085195 Nom Autors de Toro Carmena, M, Ortega Moran, L, Garcia Adrian, S, Castanon Lopez, C, Molina Villaverde, R, Marrupe Gonzalez, D, Lopez Munoz, A, Alcaraz Nunes, D, Diaz Beveridge, R, Lopez Alfonso, A et al. DOI número 10.1093/annonc/mdz155.189
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv25. doi: 10.1093/annonc/mdz155.093. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.093 Revista ANNALS OF ONCOLOGY Títol Complet KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study. Factor d'impacte 14.20 Codi 12896 PMID https://pubmed.ncbi.nlm.nih.gov/32085099 Nom Autors Chung, H, Bang, Y, Fuchs, C, Qin, S, Satoh, T, Shitara, K, Tabernero, J, Van Cutsem, E, Cao, Z, Chen, X et al. DOI número 10.1093/annonc/mdz155.093
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv154. doi: 10.1093/annonc/mdz183.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183.004 Revista ANNALS OF ONCOLOGY Títol Complet BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. Factor d'impacte 14.20 Codi 12897 PMID https://pubmed.ncbi.nlm.nih.gov/32085058 Nom Autors Anderson, L, Tabernero, J, Christy-Bittel, J, Sandor, V, Garcia Alfonso, P, Arkenau, H, Kopetz, S, Grothey, A, Van Cutsem, E, Wasan, H et al. DOI número 10.1093/annonc/mdz183.004
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv152-iv153. doi: 10.1093/annonc/mdz183.001. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183.001 Revista ANNALS OF ONCOLOGY Títol Complet Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Factor d'impacte 14.20 Codi 12898 PMID https://pubmed.ncbi.nlm.nih.gov/32085055 Nom Autors Tabernero, J, Van Cutsem, E, Bang, Y, Fuchs, C, Wyrwicz, L, Lee, K, Kudaba, I, Garrido, M, Chung, H, Castro Salguero, H et al. DOI número 10.1093/annonc/mdz183.001
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv152. doi: 10.1093/annonc/mdz183. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183 Revista ANNALS OF ONCOLOGY Títol Complet Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. Factor d'impacte 14.20 Codi 12899 PMID https://pubmed.ncbi.nlm.nih.gov/32085054 Nom Autors Golan, T, Van Cutsem, E, Macarulla, T, Hall, M, Park, J, Hochhauser, D, Arnold, D, Oh, D, Reinacher-Schick, A, Tortora, G et al. DOI número 10.1093/annonc/mdz183
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv135. doi: 10.1093/annonc/mdz154.025. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.025 Revista ANNALS OF ONCOLOGY Títol Complet Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Factor d'impacte 14.20 Codi 12900 PMID https://pubmed.ncbi.nlm.nih.gov/32085044 Nom Autors Benavides, M, Cano, T, Loupakis, F, Garrote, M Rodriguez, Rivera, F, Goldberg, R, Falcone, A, Bennouna, J, Ciardiello, F, Tabernero, J et al. DOI número 10.1093/annonc/mdz154.025
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv127. doi: 10.1093/annonc/mdz154.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.004 Revista ANNALS OF ONCOLOGY Títol Complet Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Factor d'impacte 14.20 Codi 12901 PMID https://pubmed.ncbi.nlm.nih.gov/32085018 Nom Autors Harding, J, Cleary, J, Shapiro, G, Brana, I, Moreno, V, Quinn, D, Borad, M, Loi, S, Spanggaard, I, Stemmer, S et al. DOI número 10.1093/annonc/mdz154.004
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154 Revista ANNALS OF ONCOLOGY Títol Complet An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Factor d'impacte 14.20 Codi 12902 PMID https://pubmed.ncbi.nlm.nih.gov/32085016 Nom Autors Philip, P, Bruchec, Y Le, Romano, A, Goldstein, D, Reni, M, Riess, H, O'Reilly, E, Santoro, A, Bekaii-Saab, T, Tempero, M et al. DOI número 10.1093/annonc/mdz154
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154.001. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.001 Revista ANNALS OF ONCOLOGY Títol Complet Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Factor d'impacte 14.20 Codi 12903 PMID https://pubmed.ncbi.nlm.nih.gov/32085015 Nom Autors Tempero, M, Oh, D, Macarulla, T, Reni, M, Van Cutsem, E, Hendifar, A, Waldschmidt, D, Starling, N, Bachet, J, Chang, H et al. DOI número 10.1093/annonc/mdz154.001
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv125. doi: 10.1093/annonc/mdz157.009. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.009 Revista ANNALS OF ONCOLOGY Títol Complet Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. Factor d'impacte 14.20 Codi 12904 PMID https://pubmed.ncbi.nlm.nih.gov/32085014 Nom Autors Rolling, C, Garralda, E, Fiedler, W, Matos, I, Conte, G, Raspagliesi, F, Habel, B, Baumeister, H, Ochsenreither, S, Zurlo, A et al. DOI número 10.1093/annonc/mdz157.009
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv123. doi: 10.1093/annonc/mdz157.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.004 Revista ANNALS OF ONCOLOGY Títol Complet A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. Factor d'impacte 14.20 Codi 12905 PMID https://pubmed.ncbi.nlm.nih.gov/32085008 Nom Autors Wainberg, Z, Boland, P, Lieu, C, Dayyani, F, Macarulla, T, Zhang, B, Belanger, B, Moore, Y, Wang, T, Maxwell, F et al. DOI número 10.1093/annonc/mdz157.004
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv122-iv123. doi: 10.1093/annonc/mdz157.002. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.002 Revista ANNALS OF ONCOLOGY Títol Complet Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Factor d'impacte 14.20 Codi 12906 PMID https://pubmed.ncbi.nlm.nih.gov/32085006 Nom Autors Ishii, N, Hu, Y, Chessex, A Vaslin, Pokorska-Bocci, A, Nicolas, V, Kirpicheva, Y, Zanna, C, Flaherty, K, Tabernero, J, Hyman, D et al. DOI número 10.1093/annonc/mdz157.002
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv117. doi: 10.1093/annonc/mdz156.023. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz156.023 Revista ANNALS OF ONCOLOGY Títol Complet Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS. Factor d'impacte 14.20 Codi 12907 PMID https://pubmed.ncbi.nlm.nih.gov/32084991 Nom Autors Argiles, G, Tabernero, J, Sobrero, A, Ohtsu, A, Mayer, R, Vidot, L, Moreno Vera, S, Van Cutsem, E et al. DOI número 10.1093/annonc/mdz156.023
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv110. doi: 10.1093/annonc/mdz156. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz156 Revista ANNALS OF ONCOLOGY Títol Complet Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. Factor d'impacte 14.20 Codi 12908 PMID https://pubmed.ncbi.nlm.nih.gov/32084969 Nom Autors Reni, M, Winter, J, Tortora, G, Pelzer, U, Riess, H, Chang, H, O'Reilly, E, Oh, D, Diaz, I Ales, Milella, M et al. DOI número 10.1093/annonc/mdz156
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv109. doi: 10.1093/annonc/mdz155.399. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.399 Revista ANNALS OF ONCOLOGY Títol Complet ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). Factor d'impacte 14.20 Codi 12909 PMID https://pubmed.ncbi.nlm.nih.gov/32084963 Nom Autors Van Cutsem, E, Grothey, A, Yaeger, R, Paez, D, Tabernero, J, Taieb, J, Yoshino, T, Groc, M, Vedovato, J, Chetaille, E et al. DOI número 10.1093/annonc/mdz155.399
